Historical Valuation
Propanc Biopharma Inc (PPCB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Propanc Biopharma Inc (PPCB) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.34
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Propanc Biopharma Inc (PPCB) has a current Price-to-Book (P/B) ratio of 0.51. Compared to its 3-year average P/B ratio of 2.40 , the current P/B ratio is approximately -78.76% higher. Relative to its 5-year average P/B ratio of 2.40, the current P/B ratio is about -78.76% higher. Propanc Biopharma Inc (PPCB) has a Forward Free Cash Flow (FCF) yield of approximately -27.63%. Compared to its 3-year average FCF yield of -9.37%, the current FCF yield is approximately 194.98% lower. Relative to its 5-year average FCF yield of -9.37% , the current FCF yield is about 194.98% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for PPCB competitors is 11.03, providing a benchmark for relative valuation. Propanc Biopharma Inc Corp (PPCB.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of PPCB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PPCB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PPCB currently overvalued or undervalued?
Propanc Biopharma Inc (PPCB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Propanc Biopharma Inc (PPCB) is between to according to relative valuation methord.
What is Propanc Biopharma Inc (PPCB) fair value?
PPCB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Propanc Biopharma Inc (PPCB) is between to according to relative valuation methord.
How does PPCB's valuation metrics compare to the industry average?
The average P/S ratio for PPCB's competitors is 11.03, providing a benchmark for relative valuation. Propanc Biopharma Inc Corp (PPCB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Propanc Biopharma Inc (PPCB) as of Jan 16 2026?
As of Jan 16 2026, Propanc Biopharma Inc (PPCB) has a P/B ratio of 0.51. This indicates that the market values PPCB at 0.51 times its book value.
What is the current FCF Yield for Propanc Biopharma Inc (PPCB) as of Jan 16 2026?
As of Jan 16 2026, Propanc Biopharma Inc (PPCB) has a FCF Yield of -27.63%. This means that for every dollar of Propanc Biopharma Inc’s market capitalization, the company generates -27.63 cents in free cash flow.
What is the current Forward P/E ratio for Propanc Biopharma Inc (PPCB) as of Jan 16 2026?
As of Jan 16 2026, Propanc Biopharma Inc (PPCB) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Propanc Biopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Propanc Biopharma Inc (PPCB) as of Jan 16 2026?
As of Jan 16 2026, Propanc Biopharma Inc (PPCB) has a Forward P/S ratio of 0.00. This means the market is valuing PPCB at $0.00 for every dollar of expected revenue over the next 12 months.